PD-1 inhibitors cause ILD in NSCLC patients with hypertension

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2022年 / 1925卷 / 1期
关键词：
D O I：
10.1007/s40278-022-23788-4
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：11 / 11
相关论文
共 50 条
  • [31] Combining chemotherapy with PD-1 blockade in NSCLC
    Mathew, Matthen
    Enzler, Thomas
    Shu, Catherine A.
    Rizvi, Naiyer A.
    PHARMACOLOGY & THERAPEUTICS, 2018, 186 : 130 - 137
  • [32] Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC
    Gao, Shugeng
    Li, Ning
    Gao, Shunyu
    Xue, Qi
    Ying, Jianming
    Wang, Shuhang
    Tao, Xiuli
    Zhao, Jun
    Mao, Yousheng
    Wang, Bing
    Shao, Kang
    Lei, Wendong
    Wang, Dali
    Lv, Fang
    Zhao, Liang
    Zhang, Fan
    Zhao, Ziran
    Su, Kai
    Tan, Fengwei
    Gao, Yibo
    Sun, Nan
    Wu, Dawei
    Yu, Yue
    Ling, Yun
    Wang, Zhijie
    Duan, Chunjian
    Tang, Wei
    Zhang, Lei
    He, Shun
    Wu, Ning
    Wang, Jie
    He, Jie
    JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (05) : 816 - 826
  • [33] Cutaneous reactions to PD-1 inhibitors
    Kelly, Katherine A.
    Bowers, Nathan
    Ahn, Christine
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB154 - AB154
  • [34] PD-1 inhibitors for oesophageal cancer
    Leake I.
    Nature Reviews Gastroenterology & Hepatology, 2019, 16 (12) : 706 - 706
  • [35] Adverse reactions to PD-1 inhibitors
    Cox, C.
    Abdel-Malek, L.
    Ng, J.
    Peters, P.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2018, 59 : 51 - 51
  • [36] PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus regorafenib in patients with advanced hepatocellular carcinoma after failure of sorafenib
    Xu, Yongkang
    Fu, Shumin
    Shang, Kai
    Zeng, Jiayu
    Mao, Ye
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [37] Dynamic changes of patelet-to-lymphocyte ratio predict efficacy of PD-1/PD-L1 inhibitors in NSCLC
    Zhou, F.
    Xiong, A.
    Zhou, C.
    ANNALS OF ONCOLOGY, 2019, 30
  • [38] SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges
    Yu Chen
    Min Gao
    Zhaoqin Huang
    Jinming Yu
    Xiangjiao Meng
    Journal of Hematology & Oncology, 13
  • [39] Previous exposure to bevacizumab indicated inferior benefits from PD-1/PD-L1 inhibitors in nonsquamous NSCLC
    Zhou, F.
    Pan, Y.
    Zhou, C.
    ANNALS OF ONCOLOGY, 2019, 30
  • [40] Predictive value of tumor mutational burden for PD-1/PD-L1 inhibitors in NSCLC: A meta-analysis
    Li, Wenjie
    Zhao, Yanjun
    Zhang, Hongjun
    Zheng, Wenying
    Wang, Ruixuan
    Gu, Xing
    MEDICINE, 2023, 102 (40) : E34990
12345